schizandrin b has been researched along with Pulmonary Arterial Remodeling in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Huang, W; Liang, G; Qian, J; Qian, Y; Wang, J; Wang, Z; Wu, G; You, S | 1 |
| Bu, R; Chen, Y; Fan, Y; Gao, Y; Jia, J; Li, G; Liu, L; Wu, J; Yan, D; Yang, F; Zhang, S | 1 |
2 other study(ies) available for schizandrin b and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Schizandrin B attenuates angiotensin II induced endothelial to mesenchymal transition in vascular endothelium by suppressing NF-κB activation.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cyclooctanes; Cytokines; Disease Models, Animal; Endothelium, Vascular; Fibrosis; Gene Expression Regulation; Inflammation; Lignans; Male; Mice; Mice, Inbred C57BL; NF-kappa B p50 Subunit; Oxidative Stress; Phenotype; Polycyclic Compounds; Signal Transduction; Vascular Remodeling | 2019 |
Schisandrin B displays a protective role against primary pulmonary hypertension by targeting transforming growth factor β1.
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cells, Cultured; Cyclooctanes; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; Hypertension, Pulmonary; Hypoxia; Immunochemistry; Lignans; Medicine, Chinese Traditional; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Polycyclic Compounds; Pulmonary Artery; Schisandra; Signal Transduction; Transforming Growth Factor beta1; Up-Regulation; Vascular Remodeling | 2017 |